Press release
Acute Pain Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest - DelveInsight | Vertex Pharma, Heron Therapeutics, Neumentum, Cali Biosciences
DelveInsight's report, "Acute Pain Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Acute Pain landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.
Additionally, it examines Acute Pain market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.
To Know in detail about the Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Pain Market Forecast [https://www.delveinsight.com/sample-request/acute-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Acute Pain Market Report:
*
The Acute Pain market is anticipated to increase from approximately USD 4.5 billion in 2025 to around USD 15.5 billion by 2036, registering a compound annual growth rate (CAGR) of 12% during the forecast period from 2026 to 2036.
*
In February 2026, Cidara Therapeutics announced MK-1406 (CD388) is currently being evaluated in the Phase III ANCHOR study (NCT07159763).
*
In January 2026, Merck announced The company has successfully completed a cash tender offer, conducted via its subsidiary, for the acquisition of all outstanding common shares of Cidara Therapeutics.
*
In March 2026, Cocrystalpharma announced The company plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal Acute pain with an additional Phase IIa study.
*
In February 2026, The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation for mCombriax, a vaccine developed by Moderna, for the prevention of influenza disease.
*
In April 2025, Roche announced that New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza showing a reduction in the transmission of influenza viruses.
*
The total number of incident cases of acute pain in the 7MM were around 181,208,000 in 2025.
*
The total incident cases of acute pain in the US were around 87,410,000 in 2025. These cases are anticipated to increase in the upcoming years.
*
In 2025, approximately 13% of the incident cases of acute pain were reported in Germany.
*
In 2025, type-specific incident cases of acute pain in the 7MM comprised 89,907,500; 44,622,400; and 139,849,200 cases for postoperative pain, trauma pain, and acute medical illness, respectively.
*
In 2025, there were ~20%; ~15% and ~10% cases for mild, moderate and severe, respectively, in Japan out of 7MM.
*
In Germany in 2025, approximately 20% of acute pain cases were classified as mild, 15% as moderate, and around 10% as severe out of 7MM.
*
Key Acute Pain Companies: Vertex Pharmaceuticals, Heron Therapeutics, Neumentum, Cali Biosciences, PainReform, and others.
*
Key Acute Pain Therapies: JOURNAVX (suzetrigine), ZYNRELEF (bupivacaine and meloxicam), NTM-001, CPL-01, PRF-110, and others
*
The Acute Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics.
*
In 2023, type-specific incident cases of Acute Pain in the United States were distributed as approximately 60% for trauma-related pain and 40% for other causes.
*
In the United States, severity-specific incident cases of Acute Pain were highest for moderate pain, totaling approximately 25 million cases in 2023.
*
In the seven major markets, moderate to severe cases accounted for approximately 60% of the total diagnosed cases in 2023.
Acute Pain Overview
Acute Pain is the immediate pain experienced by patients following a surgical procedure, typically lasting from a few hours to several days. It results from tissue injury, inflammation, and nerve stimulation caused during surgery. The intensity and duration of pain can vary depending on the type of surgery, patient health, and individual pain tolerance.
Get a Free sample for the Acute Pain Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/acute-pain-market [https://www.delveinsight.com/report-store/acute-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Acute Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acute Pain Epidemiology Segmentation:
The Acute Pain market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
*
Total Incident Cases of Acute Pain
*
Total Incident Cases of Acute Pain by Type
*
Severity Specific Incident Cases of Acute Pain
*
Total Treated CasesIn of Acute Pain
Download the report to understand which factors are driving Acute Pain epidemiology trends @ Acute Pain Epidemiology Forecast [https://www.delveinsight.com/sample-request/acute-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Acute Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Pain market or expected to get launched during the study period. The analysis covers Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Acute Pain Therapies and Key Companies
*
JOURNAVX (suzetrigine): Vertex Pharmaceuticals
*
ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
*
NTM-001: Neumentum
*
CPL-01: Cali Biosciences
*
PRF-110: PainReform
Discover more about therapies set to grab major Acute Pain market share @ Acute Pain Treatment Landscape [https://www.delveinsight.com/sample-request/acute-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Acute Pain Market Drivers
*
Rising Number of Surgical Procedures: Increasing volumes of orthopedic, cardiovascular, cosmetic, and general surgeries are driving demand for effective acute pain management therapies.
*
Growing Incidence of Trauma and Injury Cases: Higher rates of road accidents, sports injuries, fractures, and emergency room visits are contributing to the need for rapid pain relief solutions.
*
Advancements in Non-Opioid Pain Management: Development of novel non-opioid analgesics and multimodal pain management approaches is expanding treatment options and improving patient outcomes.
*
Increasing Focus on Enhanced Recovery After Surgery (ERAS) Programs: Hospitals are adopting ERAS protocols that emphasize effective postoperative pain control and reduced hospital stays.
Acute Pain Market Barriers
*
Concerns Regarding Opioid Abuse and Dependence: Strict regulations and concerns over addiction risks associated with opioid analgesics may limit their utilization.
*
Stringent Regulatory Requirements: Regulatory agencies require extensive safety and efficacy data, increasing development timelines and costs for new pain therapies.
*
Side Effects Associated with Pain Medications: Adverse effects such as nausea, gastrointestinal complications, respiratory depression, and sedation can impact treatment adoption.
*
Availability of Generic Alternatives: The widespread presence of low-cost generic pain medications creates pricing pressure for branded products.
Scope of the Acute Pain Market Report
*
Study Period: 2022-2036
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Acute Pain Companies: Vertex Pharmaceuticals, Heron Therapeutics, Neumentum, Cali Biosciences, PainReform, and others
*
Key Acute Pain Therapies: JOURNAVX (suzetrigine), ZYNRELEF (bupivacaine and meloxicam), NTM-001, CPL-01, PRF-110, and others
*
Acute Pain Therapeutic Assessment: Acute Pain current marketed and Acute Pain emerging therapies
*
Acute Pain Market Dynamics: Acute Pain market drivers and Acute Pain market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Acute Pain Unmet Needs, KOL's views, Analyst's views, Acute Pain Market Access and Reimbursement
To know more about Acute Pain companies working in the treatment market, visit @ Acute Pain Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/acute-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Acute Pain Market Report Introduction
2. Executive Summary for Acute Pain
3. SWOT analysis of Acute Pain
4. Acute Pain Patient Share (%) Overview at a Glance
5. Acute Pain Market Overview at a Glance
6. Acute Pain Disease Background and Overview
7. Acute Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Pain
9. Acute Pain Current Treatment and Medical Practices
10. Acute Pain Unmet Needs
11. Acute Pain Emerging Therapies
12. Acute Pain Market Outlook
13. Country-Wise Acute Pain Market Analysis (2022-2036)
14. Acute Pain Market Access and Reimbursement of Therapies
15. Acute Pain Market Drivers
16. Acute Pain Market Barriers
17. Acute Pain Appendix
18. Acute Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-pain-market-set-for-strong-expansion-through-2036-amid-rising-investment-interest-delveinsight-vertex-pharma-heron-therapeutics-neumentum-cali-biosciences]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Pain Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest - DelveInsight | Vertex Pharma, Heron Therapeutics, Neumentum, Cali Biosciences here
News-ID: 4535518 • Views: …
More Releases from ABNewswire
DigiMarCon Europe 2026Returns to Amsterdam, Bringing the Future of Digital Marke …
Amsterdam, Netherlands - DigiMarCon Europe, the premier digital marketing, media, advertising, and business conference and exhibition in the Netherlands, will return September 17-18, 2026, in Amsterdam, Netherlands. The three-day event will unite marketers, brands, agencies, technology providers, and thought leaders from around the world to explore the strategies, technologies, and trends shaping the future of digital growth.
DigiMarCon Europe 2026 will feature high-impact keynotes, hands-on master classes, and expert-led panels, delivering…
Diabetic Foot Ulcers Pipeline 2026: MOA and ROA Insights, Clinical Trials Status …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Foot Ulcers pipeline constitutes 20+ key companies continuously working towards developing 25+ Diabetic Foot Ulcers treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
WOOF Drops Four-Style Custom Dog Portrait Line: Sketch, Illustration, Caricature …
The Vogue-featured dog lifestyle brand expands its custom apparel range with four distinct portrait styles, unlimited revisions, and a preview-before-print promise. For dog parents tired of generic templates that turn every dog into the same dog.
NEW YORK, NY - Jun 2, 2026 - Custom dog portraits used to mean wall art. WOOF, the US-based dog apparel brand featured in Vogue, is moving the category onto clothes. The brand just added…
ANCA Vasculitis Market to Witness Transformational Growth Opportunities by 2036 …
The Key ANCA Vasculitis Companies in the market include - CSL, Amgen, NS Pharma, Chemocentryx, Amgen, GlaxoSmithKline, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others.
DelveInsight's "ANCA Vasculitis Market Insights, Epidemiology, and Market Forecast-2036 report offers an in-depth understanding of the ANCA Vasculitis, historical and forecasted epidemiology as well as the ANCA Vasculitis market trends in the United States, EU4…
More Releases for Pain
Enhanced Pain Relief Solutions at Advanced Pain Care
Image: https://www.globalnewslines.com/uploads/2025/03/3f3b6259bfdec02e5dcb7b9d0c838855.jpg
Advanced Pain Care is helping people who suffer from chronic pain with sophisticated, evidence-based treatments. The clinic is particularly focused on non-surgical care that improves the quality of life. With a team of highly qualified pain experts, they work with patients who have back pain, joint pain, and nerve pain.
Personalized Treatment for Every Pain Disorder
Advanced Pain Care offers treatments depending on the cause of pain. Anyone experiencing arthritis, migraine,…
Pain Finisher | Advanced Pain Relief Device
Pain Finisher is an instant pain relief device that is effective on all pains including back pain and knee pain. It is based on the TENS theory of pain management which is easy to use and safe.
By using Pain Finisher, a modern drug-free and non-invasive pain-relieving treatment method, one can get rid of the common pain creams, gels, and risky treatment methods.
So, have a pain-free life with easy-to-use pain relief…
Neuropathic Pain Market: Innovative Therapies Reshaping Chronic Pain Management
In recent years, the global Neuropathic Pain Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Neuropathic Pain Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including…
Visceral Pain Market Analysis 2024: Addressing Pain Management Challenges
The Business Research Company has released its latest global market reports, covering insights for 2024 and offering projections up to 2033.
The Business Research Company presents an extensive market research report on the Visceral Pain Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.
Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities,…
Global Post-Operative Pain Management Market: Pain Relief Goes Worldwide
Introduction:
The Global Post-Operative Pain Management Market is growing at a rapid pace. This market involves the management of pain after surgical procedures. The market has witnessed significant growth in recent years, owing to the increasing number of surgeries and the rising prevalence of chronic diseases. Pain management is an essential aspect of healthcare, as uncontrolled pain can lead to prolonged hospital stays, delayed recovery, and poor patient outcomes.
In this article,…
Post-Operative Pain Management Market By Type, By Application(Cancer Pain, Arthr …
Global Post-Operative Pain Management Market- Description
Post-operative pain management is predominantly referred to as the use of a wide array of therapies or drugs to reduce muscle and tissue spasm in patients who have recently undergone a surgical procedure. It is evident that all type of surgeries, be it major or minor cause postoperative pain in patients which in turn increases their hospital stays while burdening them with psychological and physical…
